Chambers Rebecca 4

What Happened

• Rebecca Chambers, Chief Financial Officer of Veracyte, was granted a total of 49,338 restricted stock units (RSUs) on March 6, 2026. The grant consists of 36,181 RSUs and 13,157 RSUs, reported as acquisitions at $0.00 (transaction code A). No cash was exchanged in the filing; the reported dollar amount for the acquisition is $0.

Key Details

• Transaction date: March 6, 2026. Form 4 filed March 10, 2026 (timely within the two-business-day window).
• Breakdown: 36,181 RSUs (Footnote F1) and 13,157 RSUs (Footnote F2).
• Vesting (per footnotes):
  • F1 (36,181 RSUs): 25% vests on March 2, 2027, then 1/16 of the grant vests each quarter thereafter, subject to continued employment on each vesting date.
  • F2 (13,157 RSUs): vests in full on the first anniversary of the grant, subject to continued employment.
• Price and value: acquired at $0.00 per share as awards; the filing does not state a cash value or shares owned after the transaction.
• Transaction code: A = Award/Grant. No 10b5-1 plan, tax-withholding, or late-filing flags were disclosed in the filing.

Context

• These RSUs are compensation awards subject to vesting and continued employment. Such grants are common executive compensation and do not represent an open-market purchase or sale by the insider. They increase the insider’s potential future stake if vesting conditions are met but do not indicate immediate buying or selling activity.